Comprehensive Stock Comparison
Compare Adaptive Biotechnologies Corporation (ADPT) vs Insight Molecular Diagnostics Inc. (IMDX) Stock
Analyze side-by-side fundamentals, valuation, growth, and profitability to decide which stock is the better buy.
Selected Stocks
Add up to 10 tickers. Use presets or search to get started.
Quick Verdict
| Category | Winner | Why |
|---|---|---|
| Growth |  IMDX | 25.1% revenue growth vs ADPT's 5.1% |
| Quality / Margins |  ADPT | -31.5% net margin vs IMDX's -13.8% |
| Stability / Safety | IMDX | Beta 0.43 vs ADPT's 1.31 |
| Dividends | Tie | Neither pays a meaningful dividend |
| Momentum (1Y) | ADPT | +93.4% vs IMDX's +70.1% |
| Efficiency (ROA) | ADPT | -16.2% ROA vs IMDX's -138.3% |
Who Each Stock Is For
Income & stability
IMDXDividend streak 1 yrs, beta 0.43
Growth exposure
ADPTRev growth 5.1%, EPS growth 30.8%, 3Y rev CAGR 5.1%
Long-term compounding (10Y)
ADPT-61.0% 10Y total return vs IMDX's -94.0%
Sleep-well-at-night portfolio
IMDXLower volatility, beta 0.43, current ratio 1.62x
Defensive / Recession hedge
IMDXBeta 0.43, current ratio 1.62x
Business Model
What each company does and how it makes money
Adaptive Biotechnologies is a biotechnology company that develops immune medicine platforms for diagnosing and treating diseases like cancer, autoimmune disorders, and infectious diseases. It generates revenue primarily through its clinical diagnostics segment — including its clonoSEQ test for minimal residual disease monitoring — and its translational and clinical genomics research services, with diagnostics contributing roughly 60% of revenue. The company's key advantage lies in its proprietary immune medicine platform that maps and translates the genetics of the adaptive immune system into clinical diagnostics and therapies.
Insight Molecular Diagnostics is a molecular diagnostics company that develops and commercializes proprietary laboratory-developed tests for cancer detection. It generates revenue primarily from its DetermaRx test for early-stage lung cancer and DetermaIO gene expression assay — along with biomarker discovery services for pharmaceutical companies. The company's competitive advantage lies in its proprietary gene expression technology and collaborations with major sequencing platform providers like Life Technologies.
Revenue Breakdown by Segment
How each company's revenue is distributed across its business units
Financial Metrics Comparison
Side-by-side fundamentals across 2 stocks. BestLagging
Financial Scorecard
ADPT 4IMDX 0ADPT5/6 metricsADPT2/2 metricsADPT4/6 metricsADPT6/6 metricsADPT leads in 4 of 6 categories — strongest in Financial Metrics and Valuation Metrics. 1 category is tied.
Financial Metrics (TTM)
ADPT is the larger business by revenue, generating $253M annually — 57.4x IMDX's $4M. Profitability is closely matched — net margins range from -31.5% (ADPT) to -13.8% (IMDX). On growth, IMDX holds the edge at +126.1% YoY revenue growth, suggesting stronger near-term business momentum.
| Metric | ADPTAdaptive Biotechn… | IMDXInsight Molecular… |
|---|---|---|
| RevenueTrailing 12 months | $253M | $4M |
| EBITDAEarnings before interest/tax | -$62M | -$59M |
| Net IncomeAfter-tax profit | -$80M | -$61M |
| Free Cash FlowCash after capex | -$63M | -$24M |
| Gross MarginGross profit ÷ Revenue | +71.8% | +54.7% |
| Operating MarginEBIT ÷ Revenue | -30.9% | -13.9% |
| Net MarginNet income ÷ Revenue | -31.5% | -13.8% |
| FCF MarginFCF ÷ Revenue | -24.9% | -5.4% |
| Rev. Growth (YoY)Latest quarter vs prior year | +102.4% | +126.1% |
| EPS Growth (YoY)Latest quarter vs prior year | +126.6% | +65.4% |
Valuation Metrics
| Metric | ADPTAdaptive Biotechn… | IMDXInsight Molecular… |
|---|---|---|
| Market CapShares × price | $2.4B | $95M |
| Enterprise ValueMkt cap + debt − cash | $2.4B | $90M |
| Trailing P/EPrice ÷ TTM EPS | -14.54x | -1.16x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | 13.39x | 50.34x |
| Price / BookPrice ÷ Book value/share | 11.41x | — |
| Price / FCFMarket cap ÷ FCF | — | — |
Profitability & Efficiency
ADPT delivers a -39.0% return on equity — every $100 of shareholder capital generates $-39 in annual profit, vs $-15 for IMDX.
| Metric | ADPTAdaptive Biotechn… | IMDXInsight Molecular… |
|---|---|---|
| ROE (TTM)Return on equity | -39.0% | -14.8% |
| ROA (TTM)Return on assets | -16.2% | -138.3% |
| ROICReturn on invested capital | -41.6% | — |
| ROCEReturn on capital employed | -32.0% | -127.8% |
| Piotroski ScoreFundamental quality 0–9 | 4 | 4 |
| Debt / EquityFinancial leverage | 0.44x | — |
| Net DebtTotal debt minus cash | $41M | -$5M |
| Cash & Equiv.Liquid assets | $48M | $9M |
| Total DebtShort + long-term debt | $89M | $4M |
| Interest CoverageEBIT ÷ Interest expense | -6.25x | -536.86x |
Total Returns (with DRIP)
A $10,000 investment in ADPT five years ago would be worth $3,594 today (with dividends reinvested), compared to $696 for IMDX. Over the past 12 months, ADPT leads with a +93.4% total return vs IMDX's +70.1%. The 3-year compound annual growth rate (CAGR) favors ADPT at 22.9% vs IMDX's -10.6% — a key indicator of consistent wealth creation.
| Metric | ADPTAdaptive Biotechn… | IMDXInsight Molecular… |
|---|---|---|
| YTD ReturnYear-to-date | -1.3% | -24.2% |
| 1-Year ReturnPast 12 months | +93.4% | +70.1% |
| 3-Year ReturnCumulative with dividends | +85.6% | -28.4% |
| 5-Year ReturnCumulative with dividends | -64.1% | -93.0% |
| 10-Year ReturnCumulative with dividends | -61.0% | -94.0% |
| CAGR (3Y)Annualised 3-year return | +22.9% | -10.6% |
Risk & Volatility
IMDX is the less volatile stock with a 0.43 beta — it tends to amplify market swings less than ADPT's 1.31 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. ADPT currently trades 75.6% from its 52-week high vs IMDX's 63.7% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | ADPTAdaptive Biotechn… | IMDXInsight Molecular… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.31x | 0.43x |
| 52-Week HighHighest price in past year | $20.76 | $8.51 |
| 52-Week LowLowest price in past year | $6.26 | $2.33 |
| % of 52W HighCurrent price vs 52-week peak | +75.6% | +63.7% |
| RSI (14)Momentum oscillator 0–100 | 45.1 | 48.4 |
| Avg Volume (50D)Average daily shares traded | 1.6M | 42K |
Analyst Outlook
Wall Street rates ADPT as "Buy" and IMDX as "Buy". Consensus price targets imply 93.5% upside for IMDX (target: $11) vs 35.3% for ADPT (target: $21).
| Metric | ADPTAdaptive Biotechn… | IMDXInsight Molecular… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | Buy | Buy |
| Price TargetConsensus 12-month target | $21.25 | $10.50 |
| # AnalystsCovering analysts | 17 | 11 |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | 1 |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Historical Charts
Charts are rendered on first load. Hover for details.
Chart 1Total Return — 5 Years (Rebased to 100)
| Stock | Mar 20 | Mar 26 | Change |
|---|---|---|---|
| Adaptive Biotechnol… (ADPT) | 100 | 54.67 | -45.3% |
| Insight Molecular D… (IMDX) | 100 | 12.92 | -87.1% |
Adaptive Biotechnol… (ADPT) returned -64% over 5 years vs Insight Molecular D… (IMDX)'s -93%.
Chart 2Revenue Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Adaptive Biotechnol… (ADPT) | $38M | $179M | +365.5% |
| Insight Molecular D… (IMDX) | $0.00 | $2M | — |
Insight Molecular Diagnostics Inc.'s revenue grew from $0M (2015) to $2M (2024) — a 0.0% CAGR.
Chart 3Net Margin Trend — 10 Years
| Stock | 2017 | 2024 | Change |
|---|---|---|---|
| Adaptive Biotechnol… (ADPT) | -111.4% | -89.1% | +20.0% |
| Insight Molecular D… (IMDX) | -24.6% | -32.3% | -31.0% |
Adaptive Biotechnologies Corporation's net margin went from -111% (2017) to -89% (2024).
Chart 4EPS Growth — 10 Years
| Stock | 2015 | 2024 | Change |
|---|---|---|---|
| Adaptive Biotechnol… (ADPT) | -0.41 | -1.08 | -163.4% |
| Insight Molecular D… (IMDX) | -8.32 | -4.66 | +44.0% |
Insight Molecular Diagnostics Inc.'s EPS grew from $-8.32 (2015) to $-4.66 (2024).
Chart 5Free Cash Flow — 5 Years
Adaptive Biotechnologies Corporation generated $-99M FCF in 2024 (+61% vs 2021). Insight Molecular Diagnostics Inc. generated $-21M FCF in 2024 (+44% vs 2021).
ADPT vs IMDX: Frequently Asked Questions
7 questions · data-driven answers · updated daily
01Is ADPT or IMDX a better buy right now?
Analysts rate Adaptive Biotechnologies Corporation (ADPT) a "Buy" — based on 17 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.
02Which is the better long-term investment — ADPT or IMDX?
Over the past 5 years, Adaptive Biotechnologies Corporation (ADPT) delivered a total return of -64.1%, compared to -93.0% for Insight Molecular Diagnostics Inc. (IMDX). A $10,000 investment in ADPT five years ago would be worth approximately $4K today (assuming dividends reinvested). Over 10 years, the gap is even starker: ADPT returned -61.0% versus IMDX's -94.1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
03Which is safer — ADPT or IMDX?
By beta (market sensitivity over 5 years), Insight Molecular Diagnostics Inc. (IMDX) is the lower-risk stock at 0.43β versus Adaptive Biotechnologies Corporation's 1.31β — meaning ADPT is approximately 202% more volatile than IMDX relative to the S&P 500.
04Which has better profit margins — ADPT or IMDX?
Adaptive Biotechnologies Corporation (ADPT) is the more profitable company, earning -89.1% net margin versus -32.3% for Insight Molecular Diagnostics Inc. — meaning it keeps -89.1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: ADPT leads at -90.8% versus -32.5% for IMDX. At the gross margin level — before operating expenses — ADPT leads at 59.7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
05Which pays a better dividend — ADPT or IMDX?
None of the stocks in this comparison currently pay a material dividend. All are effectively zero-yield and should be held for capital appreciation rather than income.
06Is ADPT or IMDX better for a retirement portfolio?
For long-horizon retirement investors, Insight Molecular Diagnostics Inc. (IMDX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0.43)). Both have compounded well over 10 years (IMDX: -94.1%, ADPT: -61.0%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
07What are the main differences between ADPT and IMDX?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that beat both.